Close Menu

Doing It Themselves

After a biotech stopped working on a drug to treat Duchenne muscular dystrophy, two families in the US bought the drug to develop it themselves in the hopes of helping family members, reports the Wall Street Journal. Through research foundations, the Secklers and the Wickas paid $500,000 for the drug, called halofuginone, and will pay an additional $500,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.